Livanova plc is exploring strategic options for its cardiac rhythm management (CRM) unit. The London-based company's CRM business generated $249.1 million in net sales in 2016. Key products in the unit include the Kora 250, a full-body MRI conditional pacemaker, and Platinum, a range of implantable cardiac defibrillators and cardiac resynchronization therapy devices. Outside of CRM, Livanova also has two other business franchises – cardiac surgery and neuromodulation.